tadalafil

(redirected from Adcirca)
Also found in: Thesaurus, Medical.

ta·da·la·fil

 (tə-dā′lə-fĭl′)
n.
A drug that inhibits phosphodiesterase, C22H19N3O4, used to treat erectile dysfunction by increasing the level of cyclic GMP, which increases blood flow to the erectile tissues.

[tadal-, origin unknown + -afil, phosphodiesterase inhibitor suff. (from sildenafil).]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.tadalafil - virility drug (trade name Cialis) used to treat erectile dysfunction in men
anti-impotence drug, virility drug - drug to treat impotence attributable to erectile dysfunction
Translations

tadalafil

n tadalafilo
References in periodicals archive ?
pediatric exclusivity for Adcirca tablets (tadalafil) tablets through May 21,2018.
M2 PHARMA-November 21, 2017-US FDA Grants United Therapeutics Six Additional Months of Exclusivity for Adcirca
Medication name Medication type Oral health effect(s) Fluticasone Nasal corticosteroid None reported ProAir HFA Beta2 agonist Xerostomia Adcirca Phosphodiesterast-5 None reported inhibitor Torsemide Antihypertensive None reported Warfarin Vitamin K antagonist Oral ulcers, taste distortion Ability Antipsychotic Xerostomia Pravachol Antilipemic agent None reported Spironolactone Antihypertensive, None reported diuretic Allopurinol Anti-gout None Trazadone Antidepressant Severe xerostomia Lamictal Anticonvulsant Xerostomia Colchicine Anti-gout Bosentan (generic Endothelia receptor Brandname Tracleer) antagonist, Tracleer vasodilator reported to cause periodontal bleeding.
What can you tell me about PAH and will I be on Adcirca for a long time?
8% Adcirca, Letaris, Retavio, Hypertension (PAH) Tracleer, Tyvaso, Venvatis, Flolan, Remodulin Growth Hormone 3.
The growth in revenues for the three months ended March 31, 2010, corresponds in large part to: (i) a continued increase in the number of patients being prescribed Remodulin; and (ii) sales of Tyvaso and Adcirca, which were commercially launched in the third quarter of 2009.
Adcirca (tadalafil) is indicated for improving exercise ability in pulmonary artery hypertension patients.